Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Lee, Kyung Hun ^a   Im, Seock Ah ^a   Oh, Do Youn ^a   Lee, Se Hoon ^a   Chie, Eui Kyu ^a   Han, Wonshik ^a   Kim, Dong Wan ^a   Kim, Tae You ^a   Park, In Ae ^a   Noh, Dong Young ^a   Heo, Dae Seog ^a   Ha, Sung Whan ^a   Bang, Yung Jue ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SURGICAL TECHNIQUE; TREATMENT DURATION; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENETICS; LYMPHADENECTOMY; MASTECTOMY; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROTO ONCOGENE; SEGMENTAL MASTECTOMY; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; KI-67 ANTIGEN; LYMPH NODE EXCISION; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248177270     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-63     Document Type: Article

References (30)

1. Trudeau M Charbonneau F Gelmon K Laing K Latreille J Mackey J McLeod D Pritchard K Provencher L Verma S Selection of adjuvant chemotherapy for treatment of node-positive breast cancer Lancet Oncol 2005 6 886-98 10.1016/S1470-2045(05)70424-1 16257797
2. Martin M Pienkowski T Mackey J Pawlicki M Guastalla JP Weaver C Tomiak E Al-Tweigeri T Chap L Juhos E Guevin R Howell A Fornander T Hainsworth J Coleman R Vinholes J Modiano M Pinter T Tang SC Colwell B Prady C Provencher L Walde D Rodriguez-Lescure A Hugh J Loret C Rupin M Blitz S Jacobs P Murawsky M Riva A Vogel C Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer N Engl J Med 2005 352 2302-13 10.1056/NEJMoa043681 15930421
3. Henderson IC Berry DA Demetri GD Cirrincione CT Goldstein LJ Martino S Ingle JN Cooper MR Hayes DF Tkaczuk KH Fleming G Holland JF Duggan DB Carpenter JT Frei E 3rd Schilsky RL Wood WC Muss HB Norton L Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 2003 21 976-83 10.1200/ JCO.2003.02.063 12637460
4. Mamounas EP Bryant J Lembersky B Fehrenbacher L Sedlacek SM Fisher B Wickerham DL Yothers G Soran A Wolmark N Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 J Clin Oncol 2005 23 3686-96 10.1200/ JCO.2005.10.517 15897552
5. Piccart-Gebhart MJ Procter M Leyland-Jones B Goldhirsch A Untch M Smith I Gianni L Baselga J Bell R Jackisch C Cameron D Dowsett M Barrios CH Steger G Huang CS Andersson M Inbar M Lichinitser M Lang I Nitz U Iwata H Thomssen C Lohrisch C Suter TM Ruschoff J Suto T Greatorex V Ward C Straehle C McFadden E Dolci MS Gelber RD Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 2005 353 1659-72 10.1056/NEJMoa052306 16236737
6. Romond EH Perez EA Bryant J Suman VJ Geyer CE Jr Davidson NE Tan-Chiu E Martino S Paik S Kaufman PA Swain SM Pisansky TM Fehrenbacher L Kutteh LA Vogel VG Visscher DW Yothers G Jenkins RB Brown AM Dakhil SR Mamounas EP Lingle WL Klein PM Ingle JN Wolmark N Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 2005 353 1673-84 10.1056/NEJMoa052122 16236738
7. Meterissian SH Apoptosis: Its role in the progression of and chemotherapy for carcinoma J Am Coll Surg 1997 184 658-666 9179126
8. van Slooten HJ Clahsen PC van Dierendonck JH Duval C Pallud C Mandard AM Delobelle-Deroide A van de Velde CJ van de Vijver MJ Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to onecourse of perioperative chemotherapy Br J Cancer 1996 74 78-85 8679463
9. Reed JC Double identity for proteins of the Bcl-2 family Nature 1997 387 773-6 10.1038/42867 9194558
10. Elledge RM Green S Howes L Clark GM Berardo M Allred DC Pugh R Ciocca D Ravdin P O'Sullivan J Rivkin S Martino S Osborne CK Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study J Clin Oncol 1997 15 1916-22 9164202
11. Sjostrom J Blomqvist C von Boguslawski K Bengtsson NO Mjaaland I Malmstrom P Ostenstadt B Wist E Valvere V Takayama S Reed JC Saksela E The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer Clin Cancer Res 2002 8 811-6 11895913
12. Callagy GM Pharoah PD Pinder SE Hsu FD Nielsen TO Ragaz J Ellis IO Huntsman D Caldas C Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index Clin Cancer Res 2006 12 2468-75 10.1158/1078-0432.CCR-05-2719 16638854
13. Tsutsui S Yasuda K Suzuki K Takeuchi H Nishizaki T Higashi H Era S Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer BMC Cancer 2006 6 187 1550256 16839413 10.1186/1471-2407-6-187
14. Gurova KV Kwek SS Koman IE Komarov AP Kandel E Nikiforov MA Gudkov AV Apoptosis inhibitor as a suppressor of tumor progression: Expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor Cancer Biol Ther 2002 1 39 44 12170763
15. Teixeira C Reed JC Pratt MA Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells Cancer Res 1995 55 3902-7 7641210
16. Miyashita T Krajewski S Krajewska M Wang HG Lin HK Liebermann DA Hoffman B Reed JC Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo Oncogene 1994 9 1799-805 8183579
17. Bottini A Berruti A Bersiga A Brizzi MP Brunelli A Gorzegno G DiMarco B Aguggini S Bolsi G Cirillo F Filippini L Betri E Bertoli G Alquati P Dogliotti L p53 but not bcl-2 Immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin Cancer Res 2000 6 2751-2758 10914720
18. Greene FL Page DL Fleming ID Fritz AG Balch CM Haller DG Morrow M AJCC cancer staging manual New York: Springer 6 2002
19. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:eXperience from a large study with long-term follow-up Histopathology 1991 19 403-410 10.1111/ j.1365-2559.1991.tb00229.x 1757079
20. Perou CM Sorlie T Eisen MB van de Rijn M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA Fluge O Pergamenschikov A Williams C Zhu SX Lonning PE Borresen-Dale AL Brown PO Botstein D Molecular portraits of human breast tumours Nature 2000 406 747-52 10.1038/35021093 10963602
21. Sorlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen MB van de Rijn M Jeffrey SS Thorsen T Quist H Matese JC Brown PO Botstein D Eystein Lonning P Borresen-Dale AL Geneexpression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 2001 98 10869-74 58566 11553815 10.1073/pnas.191367098
22. van de Vijver MJ He YD van't Veer LJ Dai H Hart AA Voskuil DW Schreiber GJ Peterse JL Roberts C Marton MJ Parrish M Atsma D Witteveen A Glas A Delahaye L van der Velde T Bartelink H Rodenhuis S Rutgers ET Friend SH Bernards R A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002 347 1999-2009 10.1056/NEJMoa021967 12490681
23. McDonnell TJ Korsmeyer SJ Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18) Nature 1991 349 254-256 10.1038/349254a0 1987477
24. Hamilton A Piccart M The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2 Ann Oncol 2000 11 647-63 10.1023/ A:1008390429428 10942052
25. Perez-Soler R Kemp B Wu QP Mao L Gomez J Zeleniuch-Jacquotte A Yee H Lee JS Jagirdar J Ling YH Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice Clin Cancer Res 2000 6 4932-8 11156254
26. Inoue Y Gika M Abiko T Oyama T Saitoh Y Yamazaki H Nakamura M Abe Y Kawamura M Kobayashi K Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer Oncol Rep 2005 13 259-64 15643508
27. Ferlini C Raspaglio G Mozzetti S Distefano M Filippetti F Martinelli E Ferrandina G Gallo D Ranelletti FO Scambia G Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance Mol Pharmacol 2003 64 51-8 10.1124/mol.64.1.51 12815160
28. Paik S Bryant J Tan-Chiu E Yothers G Park C Wickerham DL Wolmark N HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 J Natl Cancer Inst 2000 92 1991-8 10.1093/jnci/92.24.1991 11121461
29. Pritchard KI Shepherd LE O'Malley FP Andrulis IL Tu D Bramwell VH Levine MN National Cancer Institute of Canada Clinical Trials Group: HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 2006 354 2103-11 10.1056/NEJMoa054504 16707747
30. Hayes DF Thor A Dressler L Weaver D Broadwater G Goldstein L Martino S Ingle J Henderson IC Berry D HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344 Proc Am Soc Clin Oncol 2006 24 18S Abstract 510